Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer.

已完结 20 由 wuwu 发布于 2026/1/23 21:46:54

DOI:10.1158/0008-5472.can-25-1507
作者：Kristina Drizyte-Miller,Lars D Engstrom,Jeffrey A Klomp,Clint A Stalnecker,Addison G Stamey,Khalilah E Taylor,Mallory K Roach,Ryan Robb,Laura M Waters,Andrew Calinisan,Seamus Degan,Wen-Hsuan Chang,Xou
文献类型：期刊论文
补充材料：只需要正文

American Association for Cancer Research (AACR)

Abstract：Protein arginine methyltransferase 5 (PRMT5) is a synthetic lethal target in MTAP-deleted (MTAP-del) cancers. The MTA-cooperative PRMT5 inhibitor BMS-986504 exhibited potent and selective an

应助信息

15小时前

你我没有ta

c80c6af7f86211f09eb134735aa3bc31.pdf 已采纳

15小时前

Book学术机器人

2026/1/23 21:46:54 未找到该文献，机器人已退出，请等待人工下载

2026/1/23 21:46:54 Book学术AI机器人收到请求，开始寻找文献

2026/1/23 21:46:54 已向机器人发送请求

15小时前

wuwu 发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:Institute of Electrical and Electronics Engineers (IEEE)The optimal control of a flexible hull robotic undersea vehicle propelled by an oscillating foil